Foundation Medicine (FMI) : Traders are bullish on Foundation Medicine (FMI) as it has outperformed the S&P 500 by a wide margin of 8.98% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.84%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.28% in the last 1 week, and is up 11.69% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Foundation Medicine (NASDAQ:FMI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.94 and $23.63 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.37, notching a gain of 1.29% for the day. The total traded volume was 185,555 . The stock had closed at $24.06 on the previous day.
The stock has recorded a 20-day Moving Average of 7.39% and the 50-Day Moving Average is 17.36%. Foundation Medicine, Inc. is up 43.61% in the last 3-month period. Year-to-Date the stock performance stands at 15.72%.
Foundation Medicine (FMI) : The highest short term price target forecast on Foundation Medicine (FMI) is $23 and the lowest target price is $15. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $19 with a standard deviation of $5.66.
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patients individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products, FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and various sarcomas and pediatric cancers, are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.